This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Webcast Now Available Of Press Conference Discussing Landmark Surgery Involving Harvard Bioscience's Synthetic Trachea Scaffold And "InBreath" Bioreactor

HOLLISTON, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- An archived webcast is now available of a press conference held earlier today that detailed the first successful transplant of a regenerated trachea in the United States. The press conference was held at Children's Hospital of Illinois, where the surgery took place, and where the recipient of the implant, two-year-old Hannah Genevieve Warren, is currently recovering.

The surgery was the world's first successful pediatric regenerated trachea transplant using a synthetic scaffold. This was also the first regenerated trachea transplant surgery using a scaffold manufactured by Harvard Apparatus Regenerative Technology, Inc. (HART), the wholly owned regenerative medicine technology subsidiary of Harvard Bioscience. The implant used in the procedure was grown in one of HART's "InBreath" bioreactors.

Additional details about the surgery can be found in the press release " Harvard Apparatus Regenerative Technology's 'InBreath' Scaffold and Bioreactor Used in First U.S. Transplant of a Regenerated Trachea," released earlier today.

The archived webcast of the press conference is available at the following link: http://www.childrenshospitalofillinois.org/trachea-surgery/live-feed.html?utm_source=Newsletter&utm_medium=Email&utm_campaign=Trachea+Surgery++External+Communication

Further, the following link leads to an NBC news video describing the landmark surgery: http://www.today.com/video/today/51716123#51716123

About Harvard Bioscience

Harvard Bioscience, or HBIO, is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research and regenerative medicine. HBIO sells its products to thousands of researchers in over 100 countries primarily through its 850 page catalog (and various other specialty catalogs), its website, through distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and via our field sales organization. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden and Spain with additional facilities in France and Canada. For more information, please visit www.harvardbioscience.com .

About Harvard Apparatus Regenerative Technology, Inc.

Harvard Apparatus Regenerative Technology, Inc., a wholly owned subsidiary of Harvard Bioscience, develops and manufactures devices for use within the emerging field of regenerative medicine. These devices include bioreactors and synthetic scaffolds for growing tissue and organs outside the body; and injectors for stem cell therapy.

Stock quotes in this article: HBIO 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs